ArticleJournal of global oncology2017
Positive PD-L1 Expression Predicts Worse Outcome in Cutaneous Angiosarcoma.
Article in Journal of global oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Angiosarcoma: a systematic review of biomarkers in diagnosis, prognosis, and therapeutic strategies.Frontiers in oncology · 2025Pooled it
- PD-L1 Expression in Cutaneous Angiosarcomas: A Systematic Review with Meta-Analysis.Current oncology (Toronto, Ont.) · 2023Pooled it
- PD‑1/PD‑L1 immune checkpoint in bone and soft tissue tumors (Review).Molecular and clinical oncology · 2025Review
- Advancing Cancer Research: Current Knowledge on Cutaneous Neoplasia.International journal of molecular sciences · 2023Review
- Tumor microenvironment and its clinicopathological and prognostic associations in surgically resected cutaneous angiosarcoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Article
- Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups.Immunologic research · 2022Article
- Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center.Journal for immunotherapy of cancer · 2022Article
- The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers.Frontiers in immunology · 2022Review
- Review
- Abscopal Effects in Metastatic Cancer: Is a Predictive Approach Possible to Improve Individual Outcomes?Journal of clinical medicine · 2021Review
- Prognostic implications of PD-L1 expression in patients with angiosarcoma.Future science OA · 2021Article
- Angiosarcomas: histology, immunohistochemistry and molecular insights with implications for differential diagnosis.Histology and histopathology · 2021Review
- Review
- Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy.Molecular cancer · 2020Review
- Retrospective analysis of the prognostic value of PD-L1 expression andJournal of Cancer · 2020Article
- [Cutaneous angiosarcoma : Radiochemotherapy with liposomal pegylated doxorubicin].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2019Review
- Regulation of programmed cell death ligand 1 expression by atypical protein kinase C lambda/iota in cutaneous angiosarcoma.Cancer science · 2019Article
- Angiosarcoma with Synchronous Cutaneous and Small Bowel Involvement: A Report of a Rare Presentation.Cureus · 2018Article
- Cutaneous angiosarcoma: update on biology and latest treatment.Current opinion in oncology · 2018Review
- Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in Angiosarcoma.Frontiers in oncology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeProgrammed death-1 (PD-1) or programmed death ligand-1 (PD-L1) targeted therapies have shown promising survival outcomes in several human neoplasms. However, it is unclear whether the expression of PD-L1 can be correlated to any clinical and pathologic variables in patients with cutaneous angiosarcoma (CA). The aim of this study was to evaluate the clinicopathological significance of PD-L1 expression in CA patients. MATERIALS AND
methodsData from 52 patients with CA were retrospectively reviewed. PD-L1 expression, tumor proliferation determined by Ki-67 index, and immunohistochemical evaluation of tumor-infiltrating lymphocytes, CD4+ and CD8+, were used to determine correlation with clinicopathological variables.
resultsPD-L1 was positively expressed in 40% of all patients. PD-L1 expression was significantly associated with tumor cell proliferation. Multivariate analysis confirmed that high levels of CD8+ tumor-infiltrating lymphocytes were a significant predictor in patients with clinical stage I CA and the positive expression of PD-L1 was an independent prognostic factor in predicting worse outcome.
conclusionPD-L1 expression is a novel pathologic marker for predicting worse outcome in patients with CA.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.